Pancreatic Cancer Research

ResearcherUniversity of CopenhagenActive in the last 2 years

Carsten Palnæs Hansen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9256-2240; OpenAlex author ID A5038457626, A5128289973. Sources: ClinicalTrials.gov.

Their work

Papers
41 (first author 4, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
98
Papers, trials and grants by year

1999: 1 trial · 2000: none · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 5 papers · 2021: 6 papers · 2022: 5 papers · 2023: 7 papers · 2024: 3 papers · 2025: 5 papers · 2026: 2 papers

Papers 41

  1. Distal and Total Pancreatectomy With En Bloc Celiac Axis Resection for Pancreatic Cancer at a High-Volume Center. Co-author DOI 10.1097/as9.0000000000000688↗
  2. Young Age Is Associated with Improved Survival After Resection of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/life16091499↗
  3. Association of chemotherapy completion rates and overall survival with postoperative complications after pancreaticoduodenectomy for pancreatic ductal adenocar… First author DOI 10.1016/j.hpb.2024.11.002↗
  4. Progression of resectable pancreatic ductal adenocarcinoma during surgical delay and effects on survival - A propensity score matched study. Last author DOI 10.1016/j.pan.2024.11.015↗
  5. Preoperative EUS-guided biopsy does not affect survival in patients with pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1097/eus.0000000000000156↗
  6. Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in patients with advanced pancreatic ducta… Co-author DOI 10.1186/s12885-025-14283-w↗
  7. Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2025.1568386↗
  8. Have a vital end-user been overlooked? Developing a shared decision intervention for patients with potential pancreatic cancer regarding the choice of surgery. Co-author DOI 10.1016/j.pecinn.2024.100269↗
  9. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Co-author DOI 10.1080/00365521.2024.2378948↗
  10. Perioperative factors associated with survival following surgery for pancreatic cancer - a nationwide analysis of 473 cases from Denmark. Co-author DOI 10.1186/s12893-024-02369-4↗
  11. Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer. Co-author DOI 10.1002/cam4.5240↗
  12. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocar… Co-author DOI 10.1016/j.pan.2023.05.003↗
  13. Impact of para aortic lymph node removal on survival following resection for pancreatic adenocarcinoma. First author DOI 10.1186/s12893-023-02123-2↗
  14. High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fmolb.2023.1158058↗
  15. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1211292↗
  16. Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15030897↗
  17. Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers15143677↗
  18. Long-Term Outcomes of Venous Resections in Pancreatic Ductal Adenocarcinoma Patients: A Nationwide Cohort Study. First author DOI 10.1097/as9.0000000000000219↗
  19. Plasma Kallikrein-Activated TGF-β Is Prognostic for Poor Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma and Associates with Increased Fibro… Co-author DOI 10.3390/biom12091315↗
  20. Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14030819↗
  21. Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer. Co-author DOI 10.3390/cells11233763↗
  22. A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic C… Co-author DOI 10.3390/pharmaceutics14030509↗
  23. The psychological symptom burden in partners of pancreatic cancer patients: a population-based cohort study. Co-author DOI 10.1007/s00520-021-06251-4↗
  24. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. Co-author DOI 10.1016/j.ejca.2020.10.038↗
  25. Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival i… Co-author DOI 10.1016/j.ejca.2021.09.009↗
  26. Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma - An external validation study. Co-author DOI 10.1016/j.pan.2021.05.003↗
  27. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  28. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification. Co-author DOI 10.1158/1078-0432.ccr-20-4215↗
  29. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Co-author DOI 10.1002/ijc.32751↗
  30. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. Co-author DOI 10.1016/j.ejca.2020.01.015↗
  31. Increased psychological symptom burden in patients with pancreatic cancer: A population-based cohort study. Co-author DOI 10.1016/j.pan.2020.01.001↗
  32. Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, an… Co-author DOI 10.1097/mpa.0000000000001466↗
  33. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. Co-author DOI 10.1111/ecc.13219↗
  34. Waiting time to surgery and pancreatic cancer survival: A nationwide population-based cohort study. Co-author DOI 10.1016/j.ejso.2019.05.029↗
  35. The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. Co-author DOI 10.1080/0284186x.2019.1581374↗
  36. Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study. Co-author DOI 10.1371/journal.pone.0202486↗
  37. Incidence of pancreatic cancer in Denmark: 70 years of registration, 1943-2012. Co-author DOI 10.1080/0284186x.2017.1351036↗
  38. Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. Co-author DOI 10.1186/s40364-017-0087-6↗
  39. The Effect of Preoperative Oral Immunonutrition on Complications and Length of Hospital Stay After Elective Surgery for Pancreatic Cancer--A Randomized Control… Co-author DOI 10.1080/01635581.2016.1142586↗
  40. Danish Pancreatic Cancer Database. Co-author DOI 10.2147/clep.s99471↗
  41. [Danish Pancreatic Cancer Database]. First author PMID 23079448↗

Trials 1

  1. Pancreatic and Periampullary Tumors in Greenland Inuit Principal investigator NCT05595811↗

Closest collaborators

The 25 strongest of 98 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julia Sidenius Johansen · 20 shared papers, 2017–2025 · strength 2.84
  2. Inna Markovna Chen · 16 shared papers, 2020–2026 · strength 2.40
  3. Astrid Zedlitz Johansen · 11 shared papers, 2020–2025 · strength 1.53
  4. Stefan Kobbelgaard Burgdorf · 6 shared papers, 2022–2026 · strength 1.51
  5. Jan Henrik Storkholm · 5 shared papers, 2022–2026 · strength 1.32
  6. Martin Sillesen · 5 shared papers, 2022–2025 · strength 1.01
  7. M.A. Karsdal · 6 shared papers, 2020–2025 · strength 0.94
  8. Nicholas Willumsen · 6 shared papers, 2020–2025 · strength 0.94
  9. Claus Wilki Fristrup · 8 shared papers, 2012–2025 · strength 0.93
  10. Jens Hillingsø · 5 shared papers, 2016–2025 · strength 0.79
  11. Per Pfeiffer · 7 shared papers, 2019–2025 · strength 0.76
  12. Bojan Kovacevic · 3 shared papers, 2023–2025 · strength 0.73
  13. Lars Nannestad Jørgensen · 4 shared papers, 2022–2025 · strength 0.67
  14. Hadi M. H. Diab · 4 shared papers, 2022–2025 · strength 0.67
  15. Benjamin Emil Stubbe · 4 shared papers, 2021–2025 · strength 0.67
  16. Stine Dam Henriksen · 4 shared papers, 2021–2025 · strength 0.67
  17. Ole Thorlacius‐Ussing · 4 shared papers, 2021–2025 · strength 0.67
  18. Louise S. Rasmussen · 6 shared papers, 2019–2025 · strength 0.66
  19. Sophie Louise Gisela Kollbeck · 3 shared papers, 2023–2025 · strength 0.66
  20. Frank Viborg Mortensen · 5 shared papers, 2018–2025 · strength 0.64
  21. Jakob Kirkegård · 4 shared papers, 2018–2025 · strength 0.63
  22. Mogens Tornby Stender · 3 shared papers, 2022–2025 · strength 0.61
  23. Neel Ingemann Nissen · 4 shared papers, 2022–2023 · strength 0.61
  24. Michael Bau Mortensen · 5 shared papers, 2012–2025 · strength 0.59
  25. Rasmus S. Pedersen · 3 shared papers, 2022–2025 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.